Samsung Bioepis teams up with Takeda to develop original biotech drugs
(WorldNews Business)

* Biosimilar developer says expanding into novel drugs * Bioepis` Enbrel copy generated over $250 mln in sales since 2016 * Move is part of Samsung Group`s biopharma bet for future growth By Joyce Lee SEOUL, Aug 21 (Reuters) - Samsung Bioepis Co Ltd said on Monday it will fund and develop multiple original drugs in partnership with Japan`s Takeda Pharmaceutical Co Ltd, expanding its business scope beyond copies of existing biologic drugs. Original biotech drugs represent a business ramp-up for Samsung Bioepis, which has so far invested $1.3 billion in drug development since being founded in 2012 and has received approvals for two biosimilar drugs in Europe and one in the United...